Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jul 29, 2009
SAN DIEGO, July 29, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report second quarter 2009 financial results after the NASDAQ Global Market closes on Monday, August 3, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E....
Jul 8, 2009
SAN DIEGO, July 8, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the pricing of its public offering of 12,500,000 shares of its common stock at a public offering price of $4.17 per share. All of the shares are being offered by Arena. The gross proceeds to Arena, before expenses, fr...
Jul 7, 2009
SAN DIEGO, July 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. will be the sole underwriter for the offering. The offering is being made pursuant to a shelf registration statement filed ...
Jun 18, 2009
SAN DIEGO, June 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Piper Jaffray Fourth Annual Europe Conference on June 23, 2009 at 9:30 a.m. British Summer Time (4:30 am Eastern Time, 1:30 a.m. Pacific Time) at the Andaz Hotel in Lon...
Jun 17, 2009
SAN DIEGO, June 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with Deerfield Management, a leading healthcare investment organization and significant Arena stockholder, to provide Arena with $100 million in funding through a credit facility...
Jun 6, 2009
NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today a late-breaking poster presentation of positive results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy o...
Jun 5, 2009
SAN DIEGO, June 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 8th Annual Needham Life Sciences Conference on June 11, 2009 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the New York Palace Hotel in New York City. Robert E....
Jun 1, 2009
SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial has been accepted for a poster presentation at the American Diabetes A...
May 13, 2009
SAN DIEGO, May 13, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 34th Annual Deutsche Bank Health Care Conference on May 19, 2009 at 10:10 a.m. Eastern Time (7:10 a.m. Pacific Time) at the InterContinental Boston Hotel in Boston...
May 11, 2009
SAN DIEGO, May 11, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the first quarter ended March 31, 2009. Arena reported a net loss allocable to common stockholders in the first quarter of 2009 of $50.6 million, or $0.68 per share, compared to a net loss ...
May 5, 2009
SAN DIEGO, May 5, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first quarter 2009 financial results after the NASDAQ Global Market closes on Monday, May 11, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoff...
Mar 30, 2009
SAN DIEGO, March 30, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today positive top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight ...
Mar 29, 2009
SAN DIEGO, March 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will hold a conference call and webcast on Monday, March 30, 2009 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight a...
Mar 23, 2009
SAN DIEGO, March 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today it has obtained an equity financing commitment of up to $50 million from Azimuth Opportunity Ltd. During the 18-month term of the equity financing commitment, Arena may sell newly issued registered shares of its com...
Mar 12, 2009
SAN DIEGO, March 12, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2008. Arena reported a net loss allocable to common stockholders in the fourth quarter of 2008 of $62.5 million, or $0.84 per share, an...
= add release to Briefcase